Improved ORR, mDOR, and mPFS in patients with 1L ESCC and PD-L1 scores ≥1%1
Additional Efficacy Outcomes: ORR, mDOR, and mPFS in PD-L1 ≥1%
Efficacy analyses were descriptive only.
1L, first line, ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival. PD-L1, programmed death ligand 1.
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025.